Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yascara Grisel Luna Saavedra"'
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72113 (2013)
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative regulator of the LDL receptor (LDLR) leading to its degradation in endosomes/lysosomes and up-regulation of plasma LDL-cholesterol levels. The proprote
Externí odkaz:
https://doaj.org/article/3f3a5b059b60493ba1c1e8a48db3f826
Autor:
Doris Dea, Robert Dufour, Louise Théroux, Alexis Baass, Yascara Grisel Luna Saavedra, Judes Poirier, Martine Paquette
Publikováno v:
Journal of geriatric psychiatry and neurology. 31(2)
Background: Hypercholesterolemia is a major risk factor for the late-onset form of Alzheimer disease (AD). Loss-of-function (LOF) mutations of PCSK9 and PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and have been associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5162e81d0bae3eba71933c0e1799e3d4
https://pubmed.ncbi.nlm.nih.gov/29562810
https://pubmed.ncbi.nlm.nih.gov/29562810
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 34:2700-2705
Objective— Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a downregulator of the low density lipoprotein receptor. The aims of this cross-sectional cohort-study were to examine whether the PCSK9 R46L loss of function variant found in a co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3657e197caa778776536d6b6595a55b
https://doi.org/10.1161/atvbaha.114.304406
https://doi.org/10.1161/atvbaha.114.304406
Autor:
Nabil G. Seidah, Robert Dufour, Yascara Grisel Luna Saavedra, Alexis Baass, Ann Chamberland, Annik Prat, Fannie Lajeunesse-Trempe, Dirk L. Christensen, Lydia Kaduka, Martine Paquette
Publikováno v:
Metabolic syndrome and related disorders. 15(8)
The prevalence of metabolic syndrome (MetS) has increased dramatically in low- and middle-income countries. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in low-density lipoprotein receptor degradation, but its relationship
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a4622c1702ce6cb57267d038679364
https://pubmed.ncbi.nlm.nih.gov/28749722
https://pubmed.ncbi.nlm.nih.gov/28749722
Publikováno v:
Journal of Biological Chemistry. 287:43492-43501
PCSK9 enhances the cellular degradation of the LDL receptor (LDLR), leading to increased plasma LDL cholesterol. This multidomain protein contains a prosegment, a catalytic domain, a hinge region, and a cysteine-histidine rich domain (CHRD) composed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2eea2a514c85a90d3e9d6d0db02da63
https://doi.org/10.1074/jbc.m112.394023
https://doi.org/10.1074/jbc.m112.394023
Autor:
Alexis Baass, Yascara Grisel Luna Saavedra, Michael Chong, Robert Dufour, Martine Paquette, Guillaume Paré
Publikováno v:
Journal of clinical lipidology. 11(2)
Background Carrying a risk variant in the 9p21.3 locus represents one of the strongest genetic risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population. However, the effect of these polymorphisms in patients with fami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5882a868ad6591df7b9b5706ed05629a
https://pubmed.ncbi.nlm.nih.gov/28502497
https://pubmed.ncbi.nlm.nih.gov/28502497
Publikováno v:
Journal of clinical lipidology. 9(6)
Background Recent meta-analyses have shown a dose-dependent effect of statins therapy on the increased incidence of new-onset diabetes. Proprotein convertase subtilisin/kexin type (PCSK9) inhibitors are an important group of emerging lipid-lowering t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3752af1d89c4fe7d5a7783199b4669d0
https://pubmed.ncbi.nlm.nih.gov/26687699
https://pubmed.ncbi.nlm.nih.gov/26687699
Autor:
Maryssa Canuel, Roxane Desjardins, Robert Day, Nabil G. Seidah, Yascara Grisel Luna Saavedra, Josée Hamelin, Janice Mayne, Kévin Ly, Sophie Routhier, Claude Lazure
Publikováno v:
The Journal of biological chemistry. 289(25)
Annexin A2 (AnxA2) was reported to be an extracellular endogenous inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) activity on cell-surface LDL receptor degradation. In this study, we investigated the effect of silencing the express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47770146d78b63d5ed979945b2f333e5
https://pubmed.ncbi.nlm.nih.gov/24808179
https://pubmed.ncbi.nlm.nih.gov/24808179
Publikováno v:
Journal of Clinical Lipidology. 9:419
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d2bcb8dc4da718f5bd6e80eb7ae895
https://doi.org/10.1016/j.jacl.2015.03.024
https://doi.org/10.1016/j.jacl.2015.03.024